Literature DB >> 22645077

Genetic variation in insulin pathway genes and distal colorectal adenoma risk.

A Joan Levine1, Ugonna Ihenacho, Won Lee, Jane C Figueiredo, David J Vandenberg, Christopher K Edlund, Brian D Davis, Mariana C Stern, Robert W Haile.   

Abstract

BACKGROUND: Insulin, glucose, and other insulin-related proteins that mediate insulin signaling are associated with colorectal neoplasia risk, but associations with common genetic variation in insulin axis genes are less clear. In this study, we used a comprehensive tag single-nucleotide polymorphisms (SNPs) approach to define genetic variation in six insulin axis genes (IGF1, IGF2, IGFBP1, IGFBP3, IRS1, and IRS2) and three genes associated with estrogen signaling (ESR1, ESR2, and PGR).
METHODS: We assessed associations between SNPs and distal colorectal adenoma (CRA) risk in a case-control study of 1,351 subjects. Cases were individuals with one or more adenomas diagnosed during sigmoidoscopy, and controls were individuals with no adenomas at the sigmoidoscopy exam. We used unconditional logistic regression assuming an additive model to assess SNP-specific risks adjusting for multiple comparisons with P (act).
RESULTS: Distal adenoma risk was significantly increased for one SNP in IGF2 [per minor allele OR = 1.41; 95 % confidence interval (CI) = 1.16, 1.67; P (act) = 0.005] and decreased for an ESR2 SNP (per minor allele OR = 0.78; 95 % CI = 0.66, 0.91; P (act) = 0.041). There was no statistically significant heterogeneity of these associations by race, sex, BMI, physical activity, or, in women, hormone replacement therapy use. Risk estimates did not differ in the colon versus rectum or for smaller (<1 cm) versus larger (>1 cm) adenomas.
CONCLUSIONS: These data suggest that selected genetic variability in IGF2 and ESR2 may be modifiers of CRA risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22645077     DOI: 10.1007/s00384-012-1505-8

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  67 in total

1.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

2.  So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests.

Authors:  Karen N Conneely; Michael Boehnke
Journal:  Am J Hum Genet       Date:  2007-12       Impact factor: 11.025

3.  Energy balance modulates colon tumor growth: Interactive roles of insulin and estrogen.

Authors:  Elizabeth A Rondini; Alison E Harvey; Juan P Steibel; Stephen D Hursting; Jenifer I Fenton
Journal:  Mol Carcinog       Date:  2010-12-28       Impact factor: 4.784

4.  Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States).

Authors:  Mark P Purdue; Pamela J Mink; Patricia Hartge; Wen-Yi Huang; Saundra Buys; Richard B Hayes
Journal:  Cancer Causes Control       Date:  2005-10       Impact factor: 2.506

5.  Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice.

Authors:  Takashi Sakatani; Atsushi Kaneda; Christine A Iacobuzio-Donahue; Mark G Carter; Sten de Boom Witzel; Hideyuki Okano; Minoru S H Ko; Rolf Ohlsson; Dan L Longo; Andrew P Feinberg
Journal:  Science       Date:  2005-02-24       Impact factor: 47.728

6.  Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles.

Authors:  D O Stram; J H Hankin; L R Wilkens; M C Pike; K R Monroe; S Park; B E Henderson; A M Nomura; M E Earle; F S Nagamine; L N Kolonel
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

7.  Loss of imprinting of long QT intronic transcript 1 in colorectal cancer.

Authors:  K Tanaka; G Shiota; M Meguro; K Mitsuya; M Oshimura; H Kawasaki
Journal:  Oncology       Date:  2001       Impact factor: 2.935

8.  Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.

Authors:  K L Margolis; D E Bonds; R J Rodabough; L Tinker; L S Phillips; C Allen; T Bassford; G Burke; J Torrens; B V Howard
Journal:  Diabetologia       Date:  2004-07-14       Impact factor: 10.122

Review 9.  Insulin-like growth factors and cancer.

Authors:  Gregor Fürstenberger; Hans-Jörg Senn
Journal:  Lancet Oncol       Date:  2002-05       Impact factor: 41.316

10.  Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.

Authors:  Yoko Ito; Thibaud Koessler; Ashraf E K Ibrahim; Sushma Rai; Sarah L Vowler; Sayeda Abu-Amero; Ana-Luisa Silva; Ana-Teresa Maia; Joanna E Huddleston; Santiago Uribe-Lewis; Kathryn Woodfine; Maja Jagodic; Raffaella Nativio; Alison Dunning; Gudrun Moore; Elena Klenova; Sheila Bingham; Paul D P Pharoah; James D Brenton; Stephan Beck; Manjinder S Sandhu; Adele Murrell
Journal:  Hum Mol Genet       Date:  2008-06-09       Impact factor: 6.150

View more
  4 in total

Review 1.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Authors:  Andrew P Feinberg; Michael A Koldobskiy; Anita Göndör
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

Review 2.  Estrogen receptor beta as target for colorectal cancer prevention.

Authors:  Cecilia Williams; Alfredo DiLeo; Yaron Niv; Jan-Åke Gustafsson
Journal:  Cancer Lett       Date:  2015-12-18       Impact factor: 8.679

Review 3.  No Association between Estrogen Receptor-Β Rs4986938 and Cancer Risk: A Systematic Review and Meta-Analysis.

Authors:  Zhaofang Li; Xiaoli Yang; Rongqiang Zhang; Dandan Zhang; Baorong Li; Di Zhang; Qiang Li; Yongmin Xiong
Journal:  Iran J Public Health       Date:  2019-05       Impact factor: 1.429

4.  From genotype to functional phenotype: unraveling the metabolomic features of colorectal cancer.

Authors:  Oliver F Bathe; Farshad Farshidfar
Journal:  Genes (Basel)       Date:  2014-07-22       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.